Omnicell (NASDAQ:OMCL) Cut to Hold at StockNews.com

StockNews.com lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research report report published on Monday.

A number of other equities research analysts have also recently commented on the company. Benchmark reissued a “buy” rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. Bank of America cut their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $51.00.

Omnicell Stock Performance

NASDAQ:OMCL opened at $34.45 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The stock has a 50-day simple moving average of $39.30 and a two-hundred day simple moving average of $42.70. The firm has a market capitalization of $1.61 billion, a PE ratio of 127.60, a P/E/G ratio of 7.53 and a beta of 0.85. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Analysts forecast that Omnicell will post 1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new stake in shares of Omnicell during the 3rd quarter valued at about $753,000. Charles Schwab Investment Management Inc. raised its position in Omnicell by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after purchasing an additional 22,198 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Omnicell by 7.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after purchasing an additional 1,813 shares during the last quarter. Millrace Asset Group Inc. bought a new stake in shares of Omnicell in the 3rd quarter valued at approximately $1,223,000. Finally, PEAK6 Investments LLC purchased a new position in shares of Omnicell in the 3rd quarter worth approximately $448,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.